Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma
Status:
Completed
Trial end date:
2018-08-08
Target enrollment:
Participant gender:
Summary
Bendamustine is a well tolerable and very active agent in the treatment of Non Hodgkin's
lymphoma. However, in particular in aggressive B-cell lymphoma, only very few, small studies
have investigated the role of bendamustine in the treatment algorithm. The aim of the current
B-R-ENDA trial is to investigate efficacy and toxicity of the combination treatment of
bendamustine and subcutaneous rituximab in old patients or in elderly patients with high
comorbidity who do not qualify for a CHOP like treatment. The results of this study will form
the basis of a larger, prospective randomized phase III trial.